

## DAFTAR PUSTAKA

- Alsaleh, A., Sanders, T. A. B., & O'Dell, S. D. 2012. Postgraduate Symposium Effect of interaction between PPARG , PPARA and ADIPOQ gene variants and dietary fatty acids on plasma lipid profile and adiponectin concentration in a large intervention study Proceedings of the Nutrition Society. *In Proceedings of the Nutrition Society*. pp. 141–153.
- Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Hakkinen A, Olofsson SO, Yki-Jarvinen H, et al. 2006. Overproduction of large VLDL particles is driven by increased liver fat content in man. *Diabetologia*. 49(4):755-765.
- Adam, J.M.F., 2009. Sudoyono, Dislipidemia.. *Buku Ajar Ilmu Penyakit Dalam*. Jilid III. Edisi V. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI, 1926 - 1932.
- Albright AL and Stern JS. 1998. Adipose tissue. In : Encyclopedia of sport medicine and science. TD Fahey (Editor). *Interneational society for sport science*
- Albuquerque D, Stice E, Rodriguez-Lopez R, Mancp L, Nobrega C., 2015. Cuurent review of genetics of human obesity: from molecular mechanism to an evolutionary perspective. Springer. *Molecular Genetics and Genomics*. 290 (4): 1191-1221
- Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ. 2005. Value of high- density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veterans affairs HDL intervention trial. *Arteriosclerosis Thrombo Vascular Biology*. 25:2185–2191
- Auboeuf, D., Rieusset, J., Fajas, L., Vallier, P., Frering, V., Riou, J. P., Vidal, H. 1997. Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator-Activated Receptors and Liver X Receptor-a in Humans. *J Diabetes*, 46(3), 1319–1327.
- Austin MA, King MC, Vranizan KM, Krauss RM . 1990, Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. *Circulation*. 82:495–506

Austin MA, Talmud PJ, Luong LA, Haddad L, Day IN, Newman B, ards KL, Krauss RM, Humphries SE , 1998, Candidate-genestudies of the atherogenic lipoprotein phenotype: a sib-pair linkage analysis of DZ women twins. *American J Human Genetic*. 62:406–419

Austin MA, Talmud PJ, Farin FM, Nickerson DA, Edwards KL, Leonetti D, McNeely MJ, Viernes HM, Humphries SE, Fujimoto WY , 2004, Association of apolipoprotein A5 variants with LDL particle size and triglyceride in Japanese Americans. *Biochimical Biophysical Acta* . 1688:1–9

Austin MA, King MC, Vranizan KM, Krauss RM. 1990. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. *Circulation*. 82:495–506.

Badan Penelitian dan Pengembangan Kesehatan (Banlitbangkes) Kementerian Kesehatan Republik Indonesia. 2014. Status Gizi. In: Departemen Kesehatan Indonesia. Laporan Hasil Riset Kesehatan Dasar Indonesia tahun 2013, Riskesdas Dalam Angka. Jakarta, Indonesia. p. 386-415.

Badellino KO, Wolfe ML, Reilly MP, Rader DJ. 2006. Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. *PLoS Medical*. 3(2):e22

Baik I, Ascherio A, Rimm E et al. 2000. Adiposity and mortality in men. *American Journal of Epidemiology*. 152(3):264–71.

Bamba V and Rader DJ, 2007. Obesity and atherogenic dyslipidemia. *Gastroenterology*. 132(6).2181-2190

Barona, J. & Fernandez, M.L., 2012. Dietary Cholesterol Affects Plasma Lipid Levels, the Intravascular Processing of Lipoproteins and Reverse Cholesterol Transport without Increasing the Risk for Heart Disease. *Nutrients*. 4,1015–1025.

Barter et al., 2010. High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease S. Ernst J, ed., London: Springer.

Barter PJ: Hugh sinclair, 2002, lecture: the regulation and remodelling of HDL by plasma factors. *Atherosclerosis Supplementation* . 3(4):39-47.

- Barton, M., Baretella, O. & Meyer, M.R., 2012. Themed Section : Fat and Vascular Responsiveness Correspondence Obesity and risk of vascular disease : importance of vasoconstriction. *British journal of pharmacology*. 165, pp.591–602.
- Basak, R.C., Chatterjee, M. & Sarma, P.S.A., 2013. An overview on management of diabetic dyslipidemia. *Journal of Diabetes Endocrinol*. 4(3), pp.27–36.
- Basset J, Caterson I, Chunming C, Ikeda Y, Khalid AK, Kim YS.. 2000. The Asia Pasific Perspective : Redefining Obesity And Its Treatment. WHO : The International Association for the Study of Obesity and The International Obesity Task Force
- Bays, H. 2014. Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction. *Current opinion endocrinology diabetes obesity*. 21(5):345-351
- Benlian, P. 2001. Genetics of Dyslipidemia, London: Kluwer academic.
- Bergman RN, Van Citters GW, Mittelman SD, Dea MK, Hamilton-Wessler M, Kim SP, et al. 2001. Central role of the adipocyte in the metabolic syndrome. *J Investigative Medicine*. 49(1):119-26.
- Bergman RN, Kim SP, Catalano KJ, Hsu IR, Chiu JD, Kabir M, Hucking K, Ader M. 2006. Why visceral fat is bad: mechanisms of the metabolic syndrome. *Obesity*. 14 (Suppl 1):16S– 19S.
- Bjorntorp P. 2001. Thrifty Genes an Human Obesity. Are we chasing ghosts?. *Lancet*. 358; 1006-1008.
- Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA 2006. Obesity, Peroxisome Proliferator-Activated Reseptor and Atherosclerosis in type 2 Diabetes. *Arteriosclerosis Thrombo Vascular Biology*. 26:28-40
- Bluher, M. 2013. Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best practice & research. *Clinical endocrinology & metabolism*.27(2):163-177
- Boden G. 2004. Free fatty acid as target for therapy. *Current Opinion Endocrinology Diabetes* 11: 258-263

Boden G. 2008. Obesity and free fatty acids. *Endocrinology; Metabolism Clinical North American*. 37: 635-646

Booth ML, Chey T, Wake M, Norton K, Hesketh K, Dollman J, Robertson I. 2003. Change in the Prevalence of Overweight and Obesity Among Young Australian, 1969-1997. *American J Clinical Nutrition*;77: 29-36.

Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L. 2008, Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. *J Lipid Research*. 49(8):1746-1751.

Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, et al, 2010, Safety of anacetrapib in patients with or at high risk for coronary heart disease. *New England J Medicine*, 363(25):2406-2415.

Carr MC, Hokanson JE, Zambon A, Deeb SS, Barrett PH, Purnell JQ, Brunzell JD, 2001, The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity. *J Clinical Endocrinology Metabolism* , 86(6):2831-2837

Carl J. Lavie, Milani, R. V. & Ventura, H.O., 2009. Obesity and Cardiovascular Disease Risk Factor, Paradox, and Impact of Weight Loss. *Journal of the American College of Cardiology*, 53(21), 1925–1932.

Castelli WJ, Garrison RJ, Wilson PWF, Abbot RD, Kalousdian S, Kannel WB. 1986, Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. *J of American Medical Association*, 256:2835–2838.

Chan DC, Nguyen MN, Watts GF, Barrett PH. 2008, Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism. *J Clinical Endocrinology Metabolism* , 93(2):557-564.

Chan DC, Barrett PH, Ooi EMM, Ji J, Chan DT, Watts GF. 2009, Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. *J Clinical Endocrinology Metabolism*. 94(3): 989–997.

Chan DC, Watts GF, Nguyen MN, Barrett PHR. 2006, Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. *American J Clinical Nutrition.* 84(1):37–43.

Chakrabarti, S.K. , Wen Y, Dobrian D et al., 2011. Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats. *American J Physiology Endocrinology Metabolism.* pp.E175–E187.

Chagnon YC, Snyder EE, Walts B, Pérusse L, Weisnagel SJ, Rankinen T, and Claude Bouchar. 2004. The Human Obesity Gene Map: The 2003 Update. *Obesity Research.*, 12(3): 369-439.

Chakravarthy MV, Booth FW. 2004. Eating, Exercise, and "thrifty" Genotypes: Connecting the Dots Toward an Evolutionary Understanding of Modern Chronic Diseases. *J Applied Physiology.* 96: 3-10.

Chandra, K.S. et al., 2014. ScienceDirect Consensus statement on management of dyslipidemia in Indian subjects. *Indian Heart Journal,* 66, pp.S1–S51.

Chapman, M.J, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL. 2011. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease : evidence and guidance for management. *European Heart Journal,* 32, pp.1345–1361.

Ceshi M, Gutzwiller F, Moch H, Eichholzer M, Probst-Hensch NM. 2007. Epidemiology and pathophysiology of obesity as a cause of cancer. *Swiss Medical Weekly* 137: 50-56

Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, Chapman J, Fruchart JC, Tedgui A, Najib-Fruchart J, Staels B , 2000, CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. *Circulation* 101:2411–2417

Copeleijn E, Saris WHM, Blaak EE 2009. Metabolic flexibility in the development of insulin resistance and type 2 diabetes : effect of lifestyle. *Obesity Review* 10:178-193

- Da Luz PL, Cesena FH, Favarato D, Cerqueira ES. 2005, Comparison of serum lipid values in patients with coronary artery disease at <50, 50 to 59, 60 to 69, and >70 years of age, *American J Cardiology*. 96:1640-3.
- Da Luz, Favarato D, Faria-Neto Jr JR, Lemos P; Chagas ACP. 2008, High ratio of triglycerides to HDL-cholesterol ratio predicts extensive coronary disease. *Clinics*. 63:427-32.
- Desvergne B, Wahli W. 1999. Peroxisome proliferator-activated receptors: nuclear control of metabolism. *Endocrinology Review*. 20:649-88
- Desvergne B, Michalik L, Wahli W. 2006. Transcriptional regulation of metabolism. *Physiology Review*. 86:465-514
- Despres JP 2006. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. *European Heart Journal Supplements* .8: 84-812
- Després JP, Lemieux I, Bergeron J, Pibarot P, Mathieu, P, Larose E, Rodés-C J, Bertrand, OF, Poirier P. 2008. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. *Arteriosclerosis, thrombosis, and vascular biology J*. 28: 1039-1049
- Després JP, Arsenault BJ, Côté M, Cartier A, Lemieux I. , 2008, Abdominal obesity: the cholesterol of the 21st century? *Canadian J Cardiology*. 24 Suppl D: 7D-12D.
- De Onis, M.; Blössner, M.; Borghi, E. 2010. Global prevalence and trends of overweight and obesity among preschool children. *American Journal of Clinical Nutrition*. 92: 1257-1264.
- Dubois SG, Heilbronn LK, Smith SR. 2006. Look AHEAD Adipose Research Group. Decreased expression of adipogenic genes in obese subjects with type 2 diabetes. *Obesity*. 14: 1543–1552.
- Ducharme NA, Bickel PE 2008. Minireview : Lipid droplet in lipogenesis and lipolysis. *Endocrinology*. 149 : 942-949
- Dinas Kesehatan Propinsi Lampung. 2012. Profil Kesehatan Propinsi Lampung Tahun 2012.

- Ekmen, N., Helvacı, A., Gunaldi, M., & Sasani, H. 2015. ScienceDirect Leptin as an important link between obesity and cardiovascular risk factors in men with acute myocardial infarction. *Indian Heart Journal*, 68(2), 132–137.
- Enriori PJ, Evans AE, Sinnayah P, Cowley M. 2006. Leptin Resistance and Obesity. *Obesity*. 14(5):254S-258S
- Evans JL, Goldfine ID, Maddux BA, Grodsky GM 2003. Oxidative stress and stress activated signaling pathway: A unifying hypothesis of type 2 diabetes. *Diabetes Care*. 52: 1-8
- Ezquerra, E. A., Castellano Vázquez, J. M., Barrero, A. A., & Alegría, E. 2008. Obesity, Metabolic Syndrome, and Diabetes: Cardiovascular Implications and Therapy. *Revista Espanola Cardiologia*, 61(7), 752–64.
- Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. 2006. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. *Progress in Lipid Research* . 45:120-59
- Ferranti SD and Mozaffarian D. 2008. The Perfect Storm: Obesity, Adipocyte Dysfunction, and Metabolik consequences. *Clinical Chemistry*. 54: 945-955
- Fesinmeyer et al., 2013. Genetic risk factors for body mass index and obesity in an ethnically diverse population: results from the Population Architecture using Genomics and Epidemiology (PAGE) Study. *NIH-PA Author Manuscrit*, 21(4), pp.1–21.
- Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE. 2000. Variation in the PPAR\_ gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. *Diabetologia* . ;43:673–680.
- Francis, Gordon A., Jean-Sebastien Annicotte, and Johan Auwerx. 2003. PPARs effects on the heart and other vascular tissues. *American J Physiology Heart Circulatory Physiology*. 285: H1–H9
- Fruchart JC, Duriez P, Staels B. 1999, Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism,vascular inflammation and atherosclerosis. *Current Opinion Lipidol*. 10:245–257.

- Fruchbeck, G., Gomez-ambrosi, J., Muzurabal, fransisco jose, & Burrell, M. A. 2001. Invited Review: The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. *American J Endocrinology Metabolism.* (280), E827–847.
- Fleiss JL, 1981. Statistical Methods for Rates and Proportions. John Wiley & Sons,
- Fong BS, Rodrigues PO, Salter AM, Yip BP, Despres JP, Angel A, Gregg RE, 1985, Characterization of high density lipoprotein binding to human adipocyte plasma membranes. *J Clinical Investigation* , 75(6):1804-1812
- Fried SK and Russell CD. 1998, Diverse roles of adipose tissue in the regulation of systemic metabolism and energy balance. In:Handbook of Obesity (1st ed.), edited by Bray GA, Bouchard and James WPT. New York: Dekker, p. 397–413.
- Frohnert BI, Hui TY, Bernlohr DA . 1999. Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene. *J Biological Chemistry* 274:3970–3977
- Franssen R, Monajemi H, Stroes ESG, Kastelein JJP. 2011. Obesity and dyslipidemia. *Endocrinology and metabolism clinics of north America.* 95(5):893-902
- Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, et al, 2007, Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. *Nature* 447(7147):959-965.
- Galic S, Oakhill JS., Steinberg GR. 2010. Adipose tissue as an endocrine organ. *Molecular and Cellular Endocrinology.* 316 (2010) 129–139
- Grundy, S. M. 2016. Overnutrition, ectopic lipid and the metabolic syndrome. *Journal of Investigative Medicine*, 64(6), 1082–1086.
- Gotera W, Aryana S, Suastika K, Santoso A., Kuswardhan T. 2006. Hubungan antara obesitas sentral dengan adiponektin pada pasien geriatri dengan penyakit jantung koroner. *J Peny Dalam.* 2006;7(2):102-07.
- Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorfer A, Beere PA, Watson DJ, et al, 2000, Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the

- Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). *Circulation*, 101(5):477-484.
- Goosen GH, 2008, The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. *Physiology Behaviour*, 94(2):206-218.
- Greenstein B & Wood DF., 2006. Sistem Endokrine at Glance. Homeostasis Energy and Obesity. 2<sup>nd</sup> Ed. Jakarta. P 92-99.
- Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska M, et al. 2009. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. *Circulation*. 119:1661–1670
- Hill, M.J, Metcalfe, D., McTernan, P.G., 2009. Review: obesity and diabetes: lipids, ‘nowhere to run to’. *Clinical science*. 116: 113-123.
- Hirano, T., Ito, Y., Yoshino, G. 2005. Measurement of small dense low-density lipoprotein particles. *J Atherosclerosis thrombo vascular biology*. 12(2):67-72
- Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. 1991, Usefulness of the total cholesterol to high-density lipoprotein cholesterol ratio in predicting angiographic coronary artery disease in women. *American J Cardiologi*. 68:1646–1650.
- Hwang YC, Fujimoto WY, Hayashi T, Kahn SE, Leonetti DL, Boyko EJ. 2016. Increased Visceral Adipose Tissue is an Independent predictor for future development of atherogenic dyslipidemia. 101(2):678-685
- Ide, T., Shimano, H., Yoshikawa, T., Yahagi, N., Amimya-Kudo, M., Matsuzaka, T., ... Yamada, N. 2003. Cross-Talk between Peroxisome Proliferator-Activated Receptor (PPAR) α and Liver X Receptor (LXR) in Nutritional Regulation of Fatty Acid Metabolism. II. LXRs Suppress Lipid Degradation Gene Promoters through Inhibition of PPAR Signaling. *Molecular Endocrinology*, 17, 1255–1267.
- IDF (International Diabetes Federation). 2006. The IDF concensus worldwide definition of the metabolic syndrome.
- Indra, M. R. 2006. Dasar Genetik Obesitas Viseral. *J Kedokteran Brawijaya*, 22(4), 11–19.

- Ikeoka D, Mader JK., Pieber, TH., 2010. Adipose Tissue, Inflammation and Cardiovascular Disease. *56(1)*; 116-21
- Jellinger, P.S., Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, et al., 2012. AACE Guidelines for management of dyslipidemia and prevention of atherosclerosis. *Suppl. 1*: 1-58
- Jensen MD. 2008. Role of body fat distribution and the metabolic complications of obesity. *J Clinical Endocrinology Metabolism*. 93: S57–63.
- Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. 1998, Triglycerides concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study, *Circulation*. 97:1029-36
- Jeffery, E., Wing, A., Holstrup., B., Sebo, Z., Kaplan, J.L, Saavedra-Pena, R., et al. 2016. The adipose tissue microenvirontment regulates depot-spesific adipogenesis in obesity. *Cellular metabolism*. 24:142-150.
- Kaplan NM, 1989, The deadly quartet. Upper body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. *Archives of Internal Medicine*, 149: 1514-20.
- Kamso, S. 2007. Dislipidemia dan obesitas sentral pada lanjut usia di Kota Padang. *J Kesehatan Masyarakat Naionals*.2(2):73-77
- Khan, T.A. et al., 2013. Apolipoprotein E genotype , cardiovascular biomarkers and risk of stroke : Systematic review and meta-analysis of 14 015 stroke cases and pooled analysis of primary biomarker data from up to 60 883 individuals. *International journal of Epidemiology*, 42(February), pp.475–492.
- Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, et al, 2011, Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. *New England J Medical*, 364(2):127-135.
- Kidani, Y. & Bensinger, S.J., 2014. LXR and PPAR as integrators of lipid homeostasis and immunity. *J Immunology Review*, 249(1), pp.72–83.
- Kontush A, Chapman MJ. 2006, Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidaemia, inflammation, and atherosclerosis. *Pharmacology Review*, 58:342–374

- Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M., & Tanabe, M. (2016). KEGG as a reference resource for gene and protein annotation. *Nucleic Acids Research*, 44(D1), D457–D462.
- Kannel WB. 2006. Cardiovascular disease preventive measures for the older patient: an epidemiologic perspective. *American J Geriatric Cardiology*. 15:382–388
- Kathiiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, et al .2009. Common variants at 30 loci contribute to polygenic dyslipidemia. *Nature Genetica* 41:56–65
- Kershaw EE and Flier JS. 2004. Adipose Tissue as an Endocrine Organ. *J Clinical Endocrinology Metabolism*, 89: 2548-2556
- Lacquemant C, Lepretre F, Pineda Torra I, Manraj M, Charpentier G, Ruiz J, Staels B, Froguel P , 2000, Mutation screening of the PPAR\_ gene in type 2 diabetes associated with coronary heart disease. *Diabetes Metabolism*. 26:393–401
- Lafontan M, Moro C, Sengenes C, Galitzky J, Crampes F, Berian M, 2005. An unsuspected metabolic role for atrial natriuretic peptides : Control of lipolysis, lipid mobilization and systemic nonesterified fatty acids levels in humans. *Arteriosclerosis ThromboVascular Biology* 25: 2032-2042
- Lau DCW, Dhillon B, Yan H, Szmitsko PE, Verma S 2005 Adipokines: molecular links between obesity and atherosclerosis. *American J Heart Circulation Physiology* 288: H2031-H2041
- Lawlor DA, Smith GD, Kelly A, Sattar N, Ebrahim S 2007. Leptin and coronary heart disease risk : Prospective case control study of British women. *Obesity*. 15: 1694-1701
- Lavie CJ, Milani RV, Ventura HO. 2005. Obesity and Cardiovascular Disease, Risk Factor, Paradox, and Impact of weight loss. *J American College Cardiology* , 53: 1925-32
- Le Lay S, Ferre P, Dugail I, 2004, Adipocyte cholesterol balance in obesity. *Biochemical Society Transactions*, 32(Pt 1):103-106.

- Lee, Y. W., Kim, P. H., Lee, W. H., & Hirani, A. a. 2011. Interleukin-4, Oxidative Stress, *Vascular Inflammation and Atherosclerosis*, 18(2), 135–144.
- Lee CD, Jacobs DR Jr, Schreiner PJ, Iribarren C, and Hankinson A, 2007. Abdominal obesity and coronary artery calcification in young adults : the Coronary Artery Risk Development in Young Adults ( CARDIA ). *American J Clinical Nutrition*, 86, pp.48–54.
- Lee, M.K., 2015. Higher association of coronary artery calcification with non - alcoholic fatty liver disease than with abdominal obesity in middle - aged Korean men : the Kangbuk Samsung Health Study. *Cardiovascular Diabetology*, pp.1–9.
- Lee, MJ., Pramyothin, P., Karastergiou, K., Fried, S.K., 2014. Deconstructing the role of glucocorticoids in adipose tissue biology and the development of central obesity. *Biochimica et Biophysica Acta*. 1842 (2014) 473–481
- Lewis FL 2002. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. *Endocrinology Review* 23 : 201-229
- Limanan, D., & Prijanti, A. R. 2013. Hantaran Sinyal Leptin dan Obesitas : Hubungannya dengan Penyakit Kardiovaskuler, 1(2).
- Listiyana AD, Mardiana, Prameswari GN. 2013. Obesitas Sentral dan Kadar Kolesterol Darah Total. *Jurnal Kesehatan Masyarakat Universitas Negeri Semarang*. 9(1);37-43.
- Liu YJ, Xu FH, Shen H, Liu YZ, Deng HY, Zhao LJ, Huang QY, Dvornyk V et al 2004.. A Follow-Up Linkage Study for Quantitative Trait Loci Contributing to Obesity-Related Phenotypes. *J Clinical Endocrinology Metabolism*; 89: 875-882.
- Lobato, N. S., Filgueira, F. P., Akamine, E. H., Tostes, R. C., Carvalho, M. H. C., & Fortes, Z. B. 2012. Mechanisms of endothelial dysfunction in obesity-associated hypertension. *Brazilian Journal of Medical and Biological Research*, 45, 392–400.
- Low, S., Chin, M. C., & Deurenberg-Yap, M. 2009. Review on epidemic of obesity. *Annals of the Academy of Medicine Singapore*, 38(1), 57–65.

- Lu, Y., & Loos, R. J. F. 2013. Obesity genomics : assessing the transferability of susceptibility loci across diverse populations. *Genomic Medicine*, 5(55), 1–14.
- Miranda, L. J.; Williams, C.; Lairon, D. 2007, Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism. *British. J. Nutrition.*, 98, 458–473.
- Mascaro C, Acosta E, Ortiz JA, Marrero PF, Hegardt FG, Haro D. 1998, Control of human muscle-type carnitine palmitoyl- transferase I gene transcription by peroxisome proliferator- activated receptor. *J Biological Chemistry*. 273:8560–8563
- Matsuzawa, Y., Shimomura, I., Nakamura, T., Keno, Y., & Tokunaga, K. 1994. Pathophysiology and pathogenesis of visceral fat obesity. *Diabetes Research and Clinical Practice*.
- Mar R, Pajukanta P, Allayee H, Groenendijk M, Dallinga-Thie G, Krauss RM, Sinsheimer JS, Cantor RM, de Bruin TW, Lusis AJ . 2004. Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. *Circulatory Research* 94:993–999
- Mandard S, Muller M, Kersten S. 2004. Peroxisome proliferator-activated receptor alpha target genes. *Cellular and Molecular Life Sciences*. 61:393-416
- Mathieu P, Lemieux I, Després, J, 2010. Obesity , Inflammation , and Cardiovascular Risk. *Clinical Pharmacology & Therapeutic*, 87(4), 407–416.
- Millan J, Pinto X, Munoz A, Zuniga M, Rubies-Prat J, Pallardo LF et al.. 2009. Lipoprotein ratios: physiological significance and clinical usefulness in *cardiovascular prevention. vascular health and risk management*. 5: 757-765
- Mooradian AD, Haas MJ, Wehmeier KR, Wong NC, 2008, Obesity-related changes in high-density lipoprotein metabolism. *Obesity*. 16(6):1152-1160.
- Motojima K, 2000, Differential effects of PPARalpha activators on induction of ectopic expression of tissue-specific fatty acid binding protein genes in the mouse liver. *International J Biochem Cellular Biology*. 32:1085–1092
- Musunuru K, Orho-Melander M, Caulfield MP, Li S, Salameh WA, Reitz RE, Berglund G, Hedblad B, Engstrom G, Williams PT, Kathiresan S, Melander O,

- Krauss RM. 2009. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. *Arteriosclerosis Thrombo Vascular Biology*. 29:1975–1980
- Musunuru K, 2010. Atherogenic Dyslipidemia: Cardiovascular Risk and Dietary Intervention. *Lipids J.* 45:907-914
- Neumeier M, Sigrüner A, Eggenhofer E, Weigert J, Weiss TS, Schaeffler A, Schlitt HJ, Aslanidis C, Piso P, Langmann T, et al. 2007. High molecular weight adiponectin reduces apolipoproteins B and E release in human hepatocytes. *Biochemical Biophysiology Research Communication*, 352(2):543-548.
- Notoatmodjo, S., 2012. Metodologi Penelitian Kesehatan. Jakarta: Rineka Cipta.
- Oku H, Matsuura F, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, Masuda D, Maeda N, Ohama T, Ishigami M, et al, 2007, Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. *FEBS Lett*, 581(26):5029-5033.
- Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A. 2006. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. *European Heart J*;26:890–896
- Opie LH 2006. The Metabolic Syndrome—Does it exist? In (Opie LH, Kasuga M, Yellon DM, eds). *Diabetes at the limit II*. Kyoto: University of Cape Town Press: pp 97-110
- Osumi T, Wen JK, Hashimoto T. 1991, Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of rat acyl-CoA oxidase gene. *Biochemical Biophysiology Research Communication*. 175:866–871
- Patel, P.S., Buras, E.D. & Balasubramanyam, A., 2013. The Role of the Immune System in Obesity and Insulin Resistance. review: *Journal of Obesity*, pp.1–9.
- Vanhoutte PM, 2009. Endothelial Dysfunction, the first step forward coronary arteriosclerosis. *Circulation*, 73(April), pp.595–601.
- Pi-Sunyer X. 2003, A clinical view of the obesity problem. *J. Science*. 299: 859-60

- Poirier, P., Giles, TD., Bray, GA., Hong, Y., Stern, JS., Pi-Sunyer, X et al. 2006. An update of the 1997 American Heart Association Scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical activity, and metabolism. *Circulation.* 113:898-918
- Prasad, D.S, Kabir Z., Dash AK, Das BC . 2011. Abdominal obesity , an independent cardiovascular risk factor in Indian subcontinent : A clinico epidemiological evidence summary. *Journal of cardiovascular disease research,* 2(4), pp.199–205.
- Prasad D.S, Kabir Z., Dash AK, Das BC.2010. Cardiovascular risk factors in developing countries: A review of clinico-epidemiological evidence. *Cardiovascular Prevention Control.* 5:115-23
- Pyrzak, B. et al., 2009. No Association Of LEPR GLN223ARG Polymorphism with Leptin, Obesity or Metabolic Disturbance In Children. *European J Medical Research,* 14, pp.201–204.
- Rachmi, C.N., Li M., Alison Baur, L., 2017. Overweight and obesity in Indonesia: prevalence and risk factors- a literature review. *Public Health.* 147: 20-29
- Rakshandehroo, M., Knoch, B., Muller, M., Kersten, S. 2010. Peroxisome proliferator-activated receptor alpha target genes. PPAR research. Redinger, RN. 2007. The Pathophysiology of Obesity and Its Clinical Manifestations. *Journal of Gastrology and Hepatology.* 3(11) ; 856-863.
- Rashid S, Uffelman KD, Lewis GF. 2002. The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. *J Diabetes Complications,* 16(1):24-28.
- Rashid S, Genest J. 2007. Effect of obesity on high-density lipoprotein metabolism. *Obesity.* 15(12):2875-2888.
- Redinger RN. 2007. The Phatophysiology of Obesity and Its Clinical Manifestations. *J gastroenterology and hepatology.* 3 (11):856-863
- Robitaille J, Brouillette C, Houde A, Lemieux S, Pe'russse L, Tchernof A, Gaudet D, Vohl MC. 2004. Association between the PPAR $\alpha$ - L126V polymorphism and components of the metabolic syndrome. *J Human Genetics,* 49:482–489.

- Reis, J.P. et al., 2014. Association Between Duration of Overall and Abdominal Obesity Beginning in Young Adulthood and Coronary Artery Calcification in Middle Age. *JAMA*, 310(3), pp.280–288.
- Rizzo, M. & Berneis, K., 2005. Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? *Journal of atherosclerosis and thrombosis*, 12(5), pp.237–239.
- Saely, CH., Geiger, K., Drexel, H. 2012. Brown versus white adipose tissue: A mini-review. *Gerontology*. 58: 15-23
- Schumaker, V.N., Phillips, M.L. & Chatterton, J.E., 1994. Advances in Protein Chemistry, Lipoproteins, Apolipoproteins, and Lipases V. N. Schumaker, ed., California.
- Silventoinen K, Rokholm B, Kaprio J, Sørensen TI., 2010. The genetic and environmental influences on childhood obesity: a systematic review of twin and adoption studies. *International Journal of Obesity*. 34(1):29–40
- Seidell, J.C, Perusse L, Despres JP, Bouchard C, 2001. Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors : the Quebec Family Study 1 – 3. *American J Clinical Nutrition*, 74, pp.315–21.
- Seidell J.C. 2007. The epidemiology of obesity. *Gastroenterology*. 132(6): 2087-2102
- Smith JD. 2009. Dysfunctional HDL as a diagnostic and therapeutic target. *Arterioscler Thromb Vascular Biology*. 2009, 30(2):151-155.
- Sinha, A., Kling, S. 2008. A Review of adolescent obesity: Prevalence, etiology and treatment. *Obesity surgery*. 19:113-120
- Shachter NS: Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. *Current Opinion in Lipidology*. 2001, 12(3):297-304
- Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horvath T, Doerries C, Heinemann M, et al. 2010: Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with

type 2 diabetes mellitus but are improved after extended- release niacin therapy. *Circulation* . 121(1):110-122

Smalinskiene, A. et al., 2013. Association between APOE , SCARB1 , PPAR  $\alpha$  polymorphisms and serum lipids in a population of Lithuanian adults. *Lipids in Health and Disease*, 12(1), p.1-10

Schoonjans K, Staels B, Auwerx J (1996a) Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. *J Lipid Research*. 37:907–925

Schoonjans K, Staels B, Auwerx J (1996b) The peroxisome pro- liferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. *Biochimica and Biophysica Acta*. 1302:93–109

Shen w, Punyanitya W, Chen J, Gallagher D, Albu J, Pi-Sunyer X, Lewis CE, Grunfield C, Heshka S, Heymsfield SB. 2006. Waist circumference Correlates with Metabolic syndrome Indicators better than Percentage Fat. *Obesity J*, 14(4): 727-736.

Shils, M.E. 2006. Modern Nutrition in Health and Disease, 10<sup>th</sup> ed., New York: Lippicott Williams & Wilkins.

Steinstra R, Duval C, Muller M, Kersten S 2007. Review article. PPARs, Obesity and inflammation. *PPAR Research*, Article ID 959774 10

Stewart PM, Boulton A, Kumar S, Clark PMS, Shackleton CHL.,1999. Cortisol Metabolism in Human Obesity: Impaired Cortisone Cortisol Conversion in Subjects with Central Obesity *J Clinical Endocrinology Metabolism* 84: 1022–1027)

Sugianti E. 2009. Faktor Risiko terhadap Obesitas Sentral pada Orang Dewasa Di DKI Jakarta. Indonesian *Journal of Clinical Nutrition*. 32(2);105-116.

Sukmawati IR, Harijanto T. 2004. Optimal cut off value for obesity: Using anthropometric indices to predict atherogenic dyslipidemia in Indonesia population.In 3rd National Obesity Symposium (NOS III).p. 87-8.

Taskinen MR, Adiels M, Westerbacka J, et al. 2011, Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. *Arteriosclerosis Thrombo Vascular Biology* ; 31:2144–2150.

Tchernof A and Despres JP. 2013. Phatophysiology of Human Visceral Obesity: An Update. *Physiological Reviews*. 93: 359-404

Tjokroprawiro A. 2008a. Cardiovascular benefit of Metformin for Pts with T2DM. Dalam : Naskah lengkap Cardiometabolic health toward-2010. Chellenges in prevention and treatment of obesity, MetS, CMR, and the CMDs, Surabaya, 27-29 Juni: 116-130

Tjokroprawiro A. 2008b. Capita Selecta in Endocrinology and Metabolism-2008. Naskah Lengkap Pendidikan Kedoteran Berkelanjutan XXIII Ilmu Penyakit Dalam 2008, Surabaya, Agustus

Torra IP, Chinetti G, Duval C, Fruchart JC, Staels B. 2001 Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. *Current Opinion Lipidol.*;12:245–254.

Tomohiro ide, Hitoshi shimano. tomohiro Yoshikawa, Naoya Yahagi, Michiyo Amemiya Kudo, Takashi Matsuzaka, Masanori Nakakuri et al. 2002. Molecular Endocrinology 17(7):1255–1267

Tai, E.S., Demissie S, Cupples LA, Corella D, Wilson PW, Scaefer EJ et al., 2002. Association Between the PPARA L162V Polymorphism and Plasma Lipid Levels, The Framingham Offspring Study. *j Arteriosclerosisr Thrombo Vascular Biology*, 22, pp.805–811.

Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N, 2008, HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. *Cellular Metabolism*, 7(5):365-375.

Takahashi N, Goto T, Kusudo T, Moriyama T, Kawada T. 2005. The structures and functions of peroxisome proliferator-activated receptors (PPARs). *Nippon Rinsho* 63:557-64

Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M1995, Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. *J Clinical Investigation*. 96(6):2758-2767.

V.Danisa., G. & Obin, M.S., 2014. “Metabolically healthy obesity”: *Origins and implications. Molecular Aspect Medicine.*, 34(1), pp.59–70.

Vassiliou G, McPherson R, 2004, A novel efflux-recapture process underlies the mechanism of high-density lipoprotein cholestryl ester-selective uptake mediated by the low-density lipoprotein receptor-related protein. *Arteriosclerosis Thrombo Vascular Biology*, 24(9):1669-1675.

Verghese PB, Arrese EL, Soulages JL, 2007, Stimulation of lipolysis enhances the rate of cholesterol efflux to HDL in adipocytes. *Molecular Cellular Biochemistry*, 302(1-2):241-248

Vohl MC, Lepage P, Gaudet D, Brewer CG, Betard C, Perron P, et al. 2000. Molecular scanning of the human PPAR $\gamma$  gene: association of the L162V mutation with hyperapobetalipoproteinemia. *J Lipid Res*. 41:945–952.

Villacorta, L, 2010. PPAR $\gamma$  and its ligands: therapeutic implications in cardiovascular disease. *J Clinical Science*, 116(3), pp.205–218.

Villeneuve, S., Brisson, D. & Gaudet, D., 2015. Influence of Abdominal Obesity on the Lipid-Lipoprotein Profile in Apoprotein E2 / 4 Carriers : The Effect of an Apparent Duality. *Journal of Lipids*, , pp.1–10.

Vohl MC, Lepage P, Gaudet D, Brewer CG,.. et al., 2000. Molecular scanning of the human PPAR $\alpha$  gene : association of the L162V mutation with hyperapobetalipoproteinemia. *Journal of lipid research*, 41, pp.945–952.

Walldius G, Junger I. 2006, The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of evidence. *J Intern Med*.259:493–519.

Wang H and Peng DQ. 2011. New insight into the mechanism of low high density lipoprotein cholesterol in obesity. *Lipids in Health and Disease*, 10:176

Wang X, Rader DJ, 2007, Molecular regulation of macrophage reverse cholesterol transport. *Current Opinion Cardiology* , 22(4):368-372.

Williams PT, 2004: The relationships of vigorous exercise, alcohol, and adiposity to low and high high-density lipoprotein-cholesterol levels. *Metabolism* , 53(6):700-709.

Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, Sowers MR., 2008. The obese without cardiometabolic risk factor clustering

- and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). *Archive International Medicine* 168: 1617–1624,
- Willer, C.J. & Mohlke, K.L., 2012. Finding genes and variants for lipid levels after genome-wide association analysis. *Current Opinion in Lipidology*.
- WHO. 2000a. Obesity: preventing and managing the global epidemic. Report on a WHO Consultation on Obesity, Geneva, 3–5 June, 1997.
- WHO/NUT/NCD/98.1. Technical Report Series Number 894. Geneva: World Health Organization.
- WHO/IASO/IOTF. 2000b. The Asia-Pacific perspective: redefining obesity and its treatment. Health Communications Australia: Melbourne. ISBN 0-9577082-1-1
- WHO. 2008. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, Desember 2008. pp 8-11
- Xiao C, Watanabe T, Zhang Y, Trigatti B, Szeto L, Connelly PW, Marcovina S, Vaisar T, Heinecke JW, Lewis GF, 2008, Enhanced cellular uptake of remnant high-density lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia. *Circuoatory Research*, 103(2):159-166.
- Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NMS 2006. Adipocyte fatty acid baindang protein is a plasma biomarker closely associated with obesity and metabolic syndrome. *Clinical Chemistry*, 52: 405-413
- Yvan-Charvet L, Bobard A, Bossard P, Massiera F, Rousset X, Ailhaud G, Teboul M, Ferre P, Dagher G, Quignard-Boulange A, 2007, In vivo evidence for a role of adipose tissue SR-BI in the nutritional and hormonal regulation of adiposity and cholesterol homeostasis. *Arteriosclerosis Thrombo Vascular Biology* , 27(6):1340-1345.
- Yusuf S, Hawken S, Öunpuu S, et al. 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*. 364: 937–952.

Yoshikawa T, Ide T, Shimano H, Yahagi N, Amemiya-Kudo M, Matsuzaka T, Yatoh S, et al. 2003, Crosstalk between peroxisome proliferator-activated receptor (PPAR)  $\alpha$  and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. *Endocrinology* 144:1240–1254

Zhang J, Fu M, Cui T, Xiong C, Xu K, Zhong W, Xiao Y, Floyd D, Liang J, Li E, Song Q, Chen YE, 2004. Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity. *Proceeding National Academy Science USA* 101: 10703–10708

Zelzer S, Fuchs N, Almer G, Raggam RB, Pruller F, et al. 2011, High density lipoprotein cholesterol level is a robust predictor of lipid peroxidation irrespective of gender, age, obesity, and inflammatory or metabolic biomarkers. *Clinical Chimical Acta* 412:1345–1349.

Zhu SK, Wang ZM, Shen W, Heymsfield SB, Heshka S, 2003. Percentage body fat ranges associated with metabolic syndrome risk: results based on the third national health and nutrition examination survey. *American J Clinical Nutrition*; 78: 228-35.

